Anterior Tibial Compartment SyndromeNIRSNCT01547013
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients
An observational study of Anterior Tibial Compartment Syndrome, run by U.S. Army Medical Research and Development Command at 3 sites in United States.
Trial summary
This is a study intended to evaluate a new device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations. The name of this technology is NIRS (near-infrared spectroscopy). Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Anterior Tibial Compartment Syndrome
- How many people
- 130 participants
- Where
- 3 sitesUnited States
- Study dates
- Feb 2012to Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Adults who have sustained major blunt and penetrating trauma, who present to Grady Memorial Hospital, Atlanta Medical Center, or Athens Regional Medical Center for treatment meeting the inclusion and exclusion
Who may be able to join
- 18-60 years of age
- Admitted to a participating trauma center (Grady, AMC, ARMC) within 12 hours of injury
- At least one uninjured upper extremity
- Patients enrolled in Cohort 2 will have a "severe leg injury" (must be one of the following locations and MOI):
- 1. Anatomic Location:
- Tibia/fibula shaft fracture
Show all 18Show fewer
- Tibial plateau fracture (Schatzker III-VI) 2. High Energy Mechanism of Injury (MOI):
- Fall from >8 foot height
- Motor vehicle collision (>15mph)
- Motor vehicle versus pedestrian accident
- High velocity gunshot wound
- Crush injury
- Sport/recreation
- Patients enrolled in Cohort 1 will meet the criteria listed below:
- No bony or vascular lower extremity injury (including femur or foot fractures)
- Admitted to the ICU for a traumatic injury (not a medical problem, such as a heart attack)
- ICU stay for at least 48 hours(patients with < 2 hours of data will be excluded)
- Patients will also be selected for each cohort (See Groups/Cohorts Section).
Who cannot join
- NIRS monitoring impediment to care
- Known prior leg fractures (not related to current injury)
- Peripheral vascular disease history or concurrent lower extremity vascular injury/surgery
- Admission for medical reasons - atraumatic (ie. myocardial infarction, sepsis…)
- Less 18 years old or greater than 60 years old
- Unable to provide informed consent, or consent cannot be obtained from a legally authorized representative, within 12 hours of injury or prior to first leg surgery, whichever comes first
Show all 14Show fewer
- Amputation/Mangled Lower Extremity
- Previous fasciotomy history of the injured leg prior to enrollment
- Complete spinal cord injuries
- Bilateral upper extremity injuries
- Participants who are in custody at presentation to the hospital
- Pregnancy
- Open injury on the injured leg that is large enough that at least one NIRS sensor cannot be safely placed over the compartment
- Spanish-speaking subjects who do not speak English will NOT be excluded. A certified translated copy of the informed consent document will used and a translator will be present for Spanish-speaking patients.
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Athens Regional Medical Center
Athens, Georgia, 30606
Grady Memorial Hospital
Atlanta, Georgia, 30303
Atlanta Medical Center
Atlanta, Georgia, 30312
About this study
Official title: Phase II The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients
This is a study intended to evaluate a new device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations. The name of this technology is NIRS (near-infrared spectroscopy). This is a prospective observational cohort study intended to gather data using NIRS among injured and noninjured extremities over time. Additionally, this data will help in establishing diagnostic perfusion value thresholds to be used in a subsequent interventional study confirming the efficacy of NIRS-based ACS monitoring.
Read the detailed description
Swelling builds up in a severely injured leg (for example, a broken leg). In up to 20% of very bad injuries, the swelling can be so great that it acts to cut off blood supply to the leg, strangulating it from the inside. When this occurs, it is called Acute Compartment Syndrome (ACS). This is a painful and bad situation, which needs to be diagnosed and then surgically treated in an urgent fashion. Currently, the standard way most physicians diagnose ACS is by clinical examination. By asking the patient questions, moving and inspecting the patient's leg and typically inserting a needle in the patient's legs to measure the amount of pressure in each leg. Physicians compile this information and make the final diagnosis. This method of diagnosis can be painful and requires measurements, sometimes invasive, to be made at points in time. ACS is a disease process that develops over time therefore someone may not have ACS at the time of examination, but may develop it several hours later. The treatment for ACS is called a fasciotomy. This treatment involves making a large incision from the knee to the ankle on each side of the lower leg.
The NIRS device has already been cleared by the FDA for detecting blood flow to the brain during anesthesia. NIRS may also be helpful in diagnosing ACS. Two of the primary advantages of this device are that it is noninvasive (not painful) and it collects data continuously, so that if the disease develops, it can be detected early and treated appropriately. In order to prove this, the device must first be tested by taking a series of measurements on people that are uninjured (control groups), those with serious leg injuries (investigational groups), and people in a critically injured state, but without leg injuries (critical controls).
The goal of this study is to collect the information necessary to understand and then create decision-making guidelines that use NIRS monitoring to diagnose and direct treatment for ACS. Information for this study will be collected in the hospital. The study participants will be grouped into 2 categories:
Cohort 1: Patients who are critically injured, but have no lower leg injuries Cohort 2: Patients who have lower leg injuries that fall into certain high-energy categories (see Eligibility Criteria, Section 7.1)
This is an observational study, which means the data collected is not intended to impact the patient's course of care. At all points in time, treatment will be directed by the patient's doctor including decisions regarding operative care, non-operative care and in-patient management. In fact, this study will be blinded, which means that the doctor treating the study patients will not be able to see the NIRS values. This study will enroll approximately 120 subjects over three sites: Athens Regional Medical Center, Atlanta Medical Center, and Grady Memorial Hospital, over a period of approximately 18 months. Participation will last for 48 hours, unless the patient develops signs of compartment syndrome in which case monitoring may be extended up to 72 hours or until completion of an assessment after the patient is treated for ACS.
Participants will undergo the following procedures:
Beyond the standard of care:
- Patient interview to collect information on medical history, medications, and mechanism of injury
- Photograph(s) will be taken to document NIRS pad placement over muscle compartments and injury severity (face will not be included).
- Ultrasound measure of the thickness of the fat layer (BX 2000) to detect the distance from the patient's skin surface to the underlying muscle
- Light scan measurement of skin color (Dermaspectrometer) to see if the patient's skin color affects NIRS readings
- Near-infrared Spectroscopy (NIRS) to measure patient's muscle oxygen levels. These devices are completely noninvasive, which means there are no sharp or painful portions of the device or measurement process. The NIRS device uses a small pad, like an EKG pad, that sticks to the patient's skin and gives off a harmless, painless light that can continually measure the patient's muscle oxygen level. These measures are recorded in the monitor and will later be downloaded and used to evaluate the device's ability to detect critical changes in muscle oxygen levels.
Standard of care:
- Data will be recorded from the patient's medical record based on procedures ordered by the patient's provider, including: lab values, Stryker measurements, vital signs.
- Among Cohort 2 patients, data associated with some surgical procedures will be collected and recorded in the operating room. This will be data that is gathered as standard of care, such as blood pressure
All of this information will be kept private and secure, and no sensitive information will be collected.
- Conditions
- Anterior Tibial Compartment Syndrome
- Medical subject headings
- Anterior Compartment Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COHORT 1 | Critical Controls: Twenty five (25) critically injured subjects with NO "severe" traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. ("Critical" CONTROLS) | |
| COHORT 2 | Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with "severe leg injuries" presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT) | |
| COHORT 2A | Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL "severe leg injuries". Unilateral injuries include patients who meet the inclusion criteria for a "severe lower extremity injury" for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg. | |
| COHORT 2B: | Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a "severe leg injury". Bilateral injury patients include patients with at least one lower extremity injury classified as "severe" based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort. | |
| COHORT 2C | Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
ACS
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2012 (estimated)
- Study startFeb 2012
- Primary completionDec 2021 (estimated)
- Study completionDec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anterior Tibial Compartment SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 130 participants (estimated)
Sponsor and investigators
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Brett Freedman, MD, Principal investigator, US Army Landstuhl Regional Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01547013
- Sponsor's protocol ID
- S-11-20
- Other IDs
- A-15808.2, I100543
- Acronym
- NIRS
- Status last verified
- Mar 2021
- First submitted
- 1 Mar 2012
- Last updated
- 26 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients
- ClinicalTrials.gov ID
- NCT01547013
- Acronym / sponsor ID
- NIRS / S-11-20
- Conditions
- Anterior Tibial Compartment Syndrome
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 130 participants (estimated)
- Lead sponsor
- U.S. Army Medical Research and Development CommandUS federal agency
- Study start
- Feb 2012 (actual)
- Primary completion
- Dec 2021 (estimated)
- Study completion
- Dec 2021 (estimated)
- First posted
- 7 Mar 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study intended to evaluate a new device that uses light to measure the amount of oxygen in the muscles of injured and non-injured legs and forearms in specific situations. The name of this technology is NIRS (near-infrared spectroscopy). This is a prospective observational cohort study intended to gather data using NIRS among injured and noninjured extremities over time. Additionally, this data will help in establishing diagnostic perfusion value thresholds to be used in a subsequent interventional study confirming the efficacy of NIRS-based ACS monitoring.
Detailed description
Swelling builds up in a severely injured leg (for example, a broken leg). In up to 20% of very bad injuries, the swelling can be so great that it acts to cut off blood supply to the leg, strangulating it from the inside. When this occurs, it is called Acute Compartment Syndrome (ACS). This is a painful and bad situation, which needs to be diagnosed and then surgically treated in an urgent fashion. Currently, the standard way most physicians diagnose ACS is by clinical examination. By asking the patient questions, moving and inspecting the patient's leg and typically inserting a needle in the patient's legs to measure the amount of pressure in each leg. Physicians compile this information and make the final diagnosis. This method of diagnosis can be painful and requires measurements, sometimes invasive, to be made at points in time. ACS is a disease process that develops over time therefore someone may not have ACS at the time of examination, but may develop it several hours later. The treatment for ACS is called a fasciotomy. This treatment involves making a large incision from the knee to the ankle on each side of the lower leg.
The NIRS device has already been cleared by the FDA for detecting blood flow to the brain during anesthesia. NIRS may also be helpful in diagnosing ACS. Two of the primary advantages of this device are that it is noninvasive (not painful) and it collects data continuously, so that if the disease develops, it can be detected early and treated appropriately. In order to prove this, the device must first be tested by taking a series of measurements on people that are uninjured (control groups), those with serious leg injuries (investigational groups), and people in a critically injured state, but without leg injuries (critical controls).
The goal of this study is to collect the information necessary to understand and then create decision-making guidelines that use NIRS monitoring to diagnose and direct treatment for ACS. Information for this study will be collected in the hospital. The study participants will be grouped into 2 categories:
Cohort 1: Patients who are critically injured, but have no lower leg injuries Cohort 2: Patients who have lower leg injuries that fall into certain high-energy categories (see Eligibility Criteria, Section 7.1)
This is an observational study, which means the data collected is not intended to impact the patient's course of care. At all points in time, treatment will be directed by the patient's doctor including decisions regarding operative care, non-operative care and in-patient management. In fact, this study will be blinded, which means that the doctor treating the study patients will not be able to see the NIRS values. This study will enroll approximately 120 subjects over three sites: Athens Regional Medical Center, Atlanta Medical Center, and Grady Memorial Hospital, over a period of approximately 18 months. Participation will last for 48 hours, unless the patient develops signs of compartment syndrome in which case monitoring may be extended up to 72 hours or until completion of an assessment after the patient is treated for ACS.
Participants will undergo the following procedures:
Beyond the standard of care:
- Patient interview to collect information on medical history, medications, and mechanism of injury
- Photograph(s) will be taken to document NIRS pad placement over muscle compartments and injury severity (face will not be included).
- Ultrasound measure of the thickness of the fat layer (BX 2000) to detect the distance from the patient's skin surface to the underlying muscle
- Light scan measurement of skin color (Dermaspectrometer) to see if the patient's skin color affects NIRS readings
- Near-infrared Spectroscopy (NIRS) to measure patient's muscle oxygen levels. These devices are completely noninvasive, which means there are no sharp or painful portions of the device or measurement process. The NIRS device uses a small pad, like an EKG pad, that sticks to the patient's skin and gives off a harmless, painless light that can continually measure the patient's muscle oxygen level. These measures are recorded in the monitor and will later be downloaded and used to evaluate the device's ability to detect critical changes in muscle oxygen levels.
Standard of care:
- Data will be recorded from the patient's medical record based on procedures ordered by the patient's provider, including: lab values, Stryker measurements, vital signs.
- Among Cohort 2 patients, data associated with some surgical procedures will be collected and recorded in the operating room. This will be data that is gathered as standard of care, such as blood pressure
All of this information will be kept private and secure, and no sensitive information will be collected.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| COHORT 1 | – | –Critical Controls: Twenty five (25) critically injured subjects with NO "severe" traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. ("Critical" CONTROLS) |
| COHORT 2 | – | –Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with "severe leg injuries" presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT) |
| COHORT 2A | – | –Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL "severe leg injuries". Unilateral injuries include patients who meet the inclusion criteria for a "severe lower extremity injury" for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg. |
| COHORT 2B: | – | –Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a "severe leg injury". Bilateral injury patients include patients with at least one lower extremity injury classified as "severe" based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort. |
| COHORT 2C | – | –Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Adults who have sustained major blunt and penetrating trauma, who present to Grady Memorial Hospital, Atlanta Medical Center, or Athens Regional Medical Center for treatment meeting the inclusion and exclusion
Key inclusion criteria (18 listed)
- 18-60 years of age
- Admitted to a participating trauma center (Grady, AMC, ARMC) within 12 hours of injury
- At least one uninjured upper extremity
- Patients enrolled in Cohort 2 will have a "severe leg injury" (must be one of the following locations and MOI):
- Tibia/fibula shaft fracture
Key exclusion criteria (14 listed)
- NIRS monitoring impediment to care
- Known prior leg fractures (not related to current injury)
- Peripheral vascular disease history or concurrent lower extremity vascular injury/surgery
- Admission for medical reasons - atraumatic (ie. myocardial infarction, sepsis…)
- Less 18 years old or greater than 60 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ACS
Time frame: 48 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2021.
Related trials for Anterior Tibial Compartment Syndrome
RecruitingObservational study
Can Near-Infrared Spectroscopy (NIRS) or Intramuscular Glucose Levels Detect Impaired Leg Compartment' Perfusion?
Compartment Syndromes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brett Freedman, MD principal investigator
US Army Landstuhl Regional Medical Center
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anterior Tibial Compartment Syndrome, run by U.S. Army Medical Research and Development Command at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ACS (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2021.